Related by context. All words. (Click for frequent words.) 72 forced expiratory volume 68 trough FEV1 65 MADRS score 63 serum potassium 62 HbA1c levels 62 lung function 62 LVEF 62 FEV1 forced expiratory 62 creatinine clearance 61 tiotropium 61 serum sodium 61 peak expiratory flow 61 Forced expiratory volume 60 virologic response 60 pulmonary capillary wedge 60 left ventricular ejection 60 baseline HbA1c 60 lispro 60 FEV 60 QTcF 60 HbA 1c levels 60 P = .# 60 fasting plasma glucose 60 #mg/day [001] 60 CrCl 59 methacholine 59 6MWD 59 alanine aminotransferase ALT 59 Crohn Disease Activity 59 plasma concentrations 59 serum urate 59 mL min 59 eGFR 59 bronchodilation 59 HBeAg seroconversion 59 CDAI score 59 IPSS 59 serum creatinine 59 plasma HCV RNA 59 ADAS cog 59 oral glucose tolerance 59 glomerular filtration rate 59 HbA1c 59 pg ml 59 alanine aminotransferase 59 pg mL 59 OGTT 59 placebo p 58 ng dL 58 mL/min/#.# m 2 58 plasma glucose 58 systolic BP 58 left ventricular systolic 58 serum phosphorus 58 HAQ DI 58 nmol L 58 mcg kg 58 peak VO2 58 Index CDAI 58 timepoint 58 β blockers 58 tirofiban 58 HbA 1c 58 Cmax 58 oxycodone CR 58 sUA 58 mg dL 58 lumbar spine BMD 58 fasting plasma glucose FPG 58 HCV RNA 58 glycated hemoglobin levels 58 baseline FEV1 58 PASI scores 58 postprandial glucose 58 hours postdose 58 placebo p = 58 pulmonary exacerbation 58 #mg/m# [001] 58 CI -#.# 58 EDSS score 58 hemoglobin A1c HbA1c 58 -#.# mg dL [002] 57 Hb A1C 57 LANTUS R 57 serum phosphate levels 57 serum testosterone 57 fluticasone salmeterol 57 pulmonary exacerbations 57 liver histology 57 infarct size 57 4mg/kg 57 A1C levels 57 mcg BID 57 Montgomery Asberg Depression 57 AUC0 57 fraction LVEF 57 primary efficacy endpoint 57 mm Hg 57 expiratory flow 57 serum concentrations 57 periprocedural 57 PSADT 57 ml kg 57 binary restenosis 57 dyspnea 57 moderate renal impairment 57 retinal thickness 57 mmol L 57 solifenacin 57 postdose 57 mcg QD 57 serum creatinine levels 57 mEq L 57 virologic failure 57 timepoints 57 aminotransferases 57 specific antigen PSA 57 incontinence episodes 57 #mg/day [002] 57 glycated hemoglobin HbA1c 57 hemoglobin A1c levels 57 #.#/#.# mmHg [001] 56 #mg/kg [002] 56 achieved ACR# 56 HOMA IR 56 mL kg 56 baseline FEV 56 postintervention 56 ALVESCO 56 QTc 56 certolizumab 56 mg TID 56 log# 56 severe exacerbations 56 renal function 56 ADAS Cog 56 IU mL 56 plasma urate 56 plasma uric acid 56 IELT 56 mL sec 56 flow mediated dilation 56 SBMs 56 Alzheimer Disease Assessment 56 #mg BID [003] 56 creatinine ratio 56 alteplase 56 insulin detemir 56 CK MB 56 sweat chloride 56 ejection fraction 56 Unified Parkinson Disease 56 salmeterol fluticasone 56 laxation 56 -#.# log# 56 mg simvastatin 56 hemoglobin concentration 56 p = .# [002] 56 mg BID 56 estimated glomerular filtration 56 racemic albuterol 56 mg kg 56 g dL 56 PSA nadir 56 ipsilateral stroke 56 achieved statistical significance 56 albumin excretion 56 urinary albumin 56 posttransplant 56 fluticasone 56 Rating Scale MADRS 56 mmHg 56 ACR# response 55 PaO 2 55 hypokalemia 55 NATRECOR R 55 OADs 55 ATACAND 55 NPH insulin 55 International Prostate Symptom 55 microalbuminuria 55 baseline A1C 55 plasma glucose levels 55 peginterferon alfa 2a 55 mg kg dose 55 Psoriasis Area 55 apnea hypopnea index 55 ropivacaine 55 % CI #.#-#.# [003] 55 p = #.# [002] 55 albuminuria 55 lopinavir r arm 55 troponin T 55 Score IPSS 55 fasting blood glucose 55 nasal symptom 55 NSTE ACS 55 #μg [001] 55 tolvaptan 55 reinfarction 55 GnRH agonist 55 annualized relapse 55 prespecified 55 nmol liter 55 mmHg diastolic 55 serum HBV DNA 55 pulmonary function 55 μg 55 #mmHg [002] 55 PREZISTA r 55 abacavir lamivudine 55 mcg 55 atheroma volume 55 Kaplan Meier analysis 55 mmol l 55 EDSS scores 55 Capacity FVC 55 titrated 55 APTIVUS r 55 gastric pH 55 mL/min/#.# m2 55 ng mL 55 g dl 55 budesonide pMDI 55 lopinavir r 55 arterial oxygen saturation 55 mg orally 55 mcg mL 55 laboratory abnormalities 55 % CI #.#-#.# [006] 55 SCr 55 plus methotrexate 55 -#.# mg dL [001] 55 MMSE score 55 aspartate aminotransferase AST 55 glycosylated hemoglobin HbA1c 55 β blocker 55 symptom severity 55 ketorolac 55 μmol L 55 fosamprenavir 55 serum urate levels 55 viral load 55 salivary cortisol 55 LPV r 55 symptomatic VTE 55 Forced Vital 55 dobutamine 55 Scale cognitive subscale 55 recurrent ischemia 55 activated partial thromboplastin 55 severe renal impairment 55 PREZISTA ritonavir 55 cardiovascular mortality 55 spontaneous bowel movements 55 macroalbuminuria 55 μg kg 55 symptom exacerbation 54 fasting insulin 54 corticosteroid dose 54 pretreatment baseline 54 mg QD 54 estimated GFR 54 placebo 54 serum testosterone levels 54 #μg [002] 54 serum aminotransferase levels 54 spirometric 54 insulin glargine 54 etanercept 54 ug kg 54 recurrent VTE 54 blood Phe 54 Score DAS# 54 exacerbations 54 serum phosphate 54 serum phosphorous 54 nicardipine 54 hemodynamic parameters 54 mm Hg systolic 54 renal dysfunction 54 extrapyramidal symptoms 54 neostigmine 54 ACR Pedi 54 serum IGF 54 virological response 54 severe hypoglycemic 54 #mg doses [002] 54 nocturnal awakenings 54 PANSS total 54 QTc interval 54 DLCO 54 CD4 + cell 54 Forced Expiratory Volume 54 QTc intervals 54 COZAAR 54 methacholine challenge 54 NIH CPSI 54 adalimumab 54 serum calcium 54 #.#mg/dL 54 pmol L 54 HIV RNA 54 FEV ^ sub 54 #mg/m# [002] 54 8mg/kg 54 HBeAg negative patients 54 ml min 54 left ventricular dysfunction 54 preintervention 54 adjunctive placebo 54 leukocyte count 54 statistically significant improvement 54 adenotonsillectomy 54 intima media thickness 54 SCIg 54 serum uric acid 54 Index CDAI score 54 primary percutaneous coronary 54 UACR 54 Secondary endpoints included 54 thrombolytic therapy 54 HBV DNA 54 coronary revascularization 54 tolterodine ER 54 exhaled nitric oxide 54 nondiabetic patients 54 GERD symptom 54 overt nephropathy 54 mg d 54 platelet reactivity 54 definite stent thrombosis 54 mg dose 54 systolic dysfunction 54 paricalcitol 54 detectable HCV RNA 54 UPDRS 54 Apidra ® 54 tapentadol ER 54 REYATAZ r arm 54 serum HCV RNA 54 bronchial hyperresponsiveness 54 aPTT 54 reach statistical significance 54 systolic 54 dapagliflozin plus 54 peginterferon alfa 2b 54 inflammatory lesions 54 tipranavir r 54 corrected QT interval 54 pulmonary arterial 54 aspartate aminotransferase 54 eplerenone 54 luminal diameter 54 Viral load 54 HbA1C levels 54 FOLFOX4 54 serologically active patients 54 #mg dose [003] 53 CDAI 53 MACCE 53 copies mL 53 concomitant medications 53 H2RAs 53 irbesartan 53 interquartile range 53 hemoglobin concentrations 53 UPDRS motor 53 virologic 53 p = NS 53 #mmHg [001] 53 log# copies mL 53 progression TTP 53 TDF FTC 53 Secondary efficacy endpoints 53 TEAEs 53 Negative Syndrome 53 demonstrated statistically significant 53 IV bolus 53 p = #.# [004] 53 asthma exacerbation 53 serum prostate 53 plus ribavirin 53 exhaled NO 53 nonsignificant 53 rosuvastatin #mg 53 bosentan 53 curve AUC 53 median PFS 53 unfractionated heparin 53 transaminase elevations 53 NYHA functional class 53 TNSS 53 calculated creatinine clearance 53 systemic corticosteroids 53 HBV DNA levels 53 undetectable HBV DNA 53 renal impairment 53 reintervention 53 #.#ng/ml 53 mitoxantrone 53 serum sodium levels 53 mIU L 53 oral prednisolone 53 -#.# ± [002] 53 SGRQ 53 nonfatal MI 53 dosing interval 53 proteinuria 53 NT proBNP 53 DAPT 53 % Confidence Interval 53 urinary excretion 53 ejection fractions 53 sustained virological response 53 hypomagnesemia 53 QD dosing 53 spirometry 53 airflow obstruction 53 neutrophil counts 53 IOP lowering 53 creatinine levels 53 LEXIVA r 53 IIIa inhibitors 53 bronchodilator 53 pressor response 53 PREZISTA r arm 53 NIHSS 53 urinary calcium excretion 53 serum magnesium 53 serum PSA 53 ABC/3TC 53 μg dL 53 undetectable HCV RNA 53 D dimer 53 adefovir 53 fasting glucose levels 53 montelukast 53 airway responsiveness 53 gadolinium enhancing lesions 53 YMRS 53 extubation 53 hour bronchodilation 53 ziprasidone 53 fibrinolysis 53 biochemical recurrence 53 abciximab 53 HDRS 53 #.#mmol L [002] 53 blood Phe levels 53 FFNS 53 secondary endpoint 53 GFR 53 inspiratory 53 postoperatively 53 hypertensives 53 antiretroviral naive 53 serum cortisol 52 oral olanzapine 52 log# reduction 52 ADHD RS 52 A1c levels 52 steroid dexamethasone 52 myocardial reperfusion 52 indinavir 52 IBDQ 52 ≥ 52 ventilatory 52 uM 52 mmHg systolic 52 Knodell necroinflammatory score 52 systolic blood pressure 52 glulisine 52 rimonabant #mg 52 Montgomery Åsberg Depression 52 PANSS scores 52 biochemical relapse 52 Visual Analogue Scale VAS 52 diameter stenosis 52 SpO 2 52 cerebral oxygenation 52 Secondary endpoints 52 MADRS 52 SUVmax 52 acetazolamide 52 carotid intima media 52 confidence interval CI 52 seroconversion 52 hsCRP levels 52 primary hypercholesterolemia 52 oral antidiabetic medication 52 tertile 52 clinically meaningful improvement 52 saline placebo 52 Thrombolysis 52 EDARBI 52 iPTH 52 airway inflammation 52 thromboembolic events 52 azacitidine 52 tacrolimus 52 lowest tertile 52 WOMAC pain 52 fructosamine 52 lipid parameters 52 subclinical hypothyroidism 52 intravenous diuretics 52 procalcitonin 52 seropositive patients 52 clinically meaningful improvements 52 lopinavir ritonavir 52 glycosylated hemoglobin 52 BENICAR HCT 52 mcg Albuferon 52 ACR# responses 52 LATUDA 52 NYHA class 52 desvenlafaxine succinate 52 sustained virologic response 52 lactate dehydrogenase 52 ALT normalization 52 nausea photophobia 52 posttreatment 52 SELENA SLEDAI score 52 CFQ R 52 Secondary endpoints include 52 mcg dose 52 BYSTOLIC 52 aldosterone antagonists 52 DOXIL 52 5-FU/LV 52 % CI #.#-#.# [007] 52 #.#/#.# mm Hg [003] 52 CIMZIA TM 52 Qmax 52 Lantus ® 52 HbA1C 52 QRS duration 52 statistically significant reduction 52 SGPT 52 vecuronium 52 Non inferiority 52 highest tertile 52 hematological parameters 52 NATRECOR ® 52 gout flares 52 postprocedure 52 serum ALT 52 nonresponders 52 mild renal insufficiency 52 peptide BNP 52 cirrhotic patients 52 CK # plasma concentrations 52 ejection fraction EF 52 p = 52 antihypertensive medications 52 NIHSS score 52 insulin glargine rDNA origin 52 nonobstructive CAD 52 dalteparin 52 ‰ ¥ 52 triglyceride concentrations 52 pharmacokinetic parameters 52 demonstrated clinically meaningful 52 imatinib therapy 52 log# IU mL 52 fractional shortening 52 arterial stiffness 52 nadolol 52 #.#mmHg 52 Apgar scores 52 cerebrovascular events 52 State Examination MMSE 52 BPH Symptom Score 52 vasopressor 52 plasma folate 52 LV dysfunction 52 per deciliter mg 52 Fasting plasma glucose 52 Patency 52 potent CYP#A# inhibitors 52 VT VF 52 Serum creatinine 52 INVEGA ® 52 atazanavir ritonavir 52 Scale EDSS 52 postoperative mortality 52 treatment emergent adverse 52 QTc prolongation 52 mL 52 amoxicillin clavulanate 52 aminotransferase elevations greater 52 glycoprotein IIb IIIa inhibitors 52 Q2W 52 lactate dehydrogenase LDH 52 prednisone prednisolone 52 AGILECT R 52 IFN alfa 52 insulin lispro 52 glycated hemoglobin 52 HIV HCV coinfected 52 ACE inhibitor ramipril 52 Fasting blood glucose 52 lipid lowering agents 52 virologic breakthrough 52 complete cytogenetic response 52 diuretic chlorthalidone 52 systemic corticosteroid 51 reperfusion 51 inhaled glucocorticoids 51 statistically significant p 51 lactulose 51 ACTEMRA TM 51 plus dexamethasone 51 angiotensin II receptor blockers 51 plus MTX 51 statistically significant 51 salivary flow 51 symptom onset 51 thromboembolic 51 glimepiride 51 secondary endpoints 51 nonfatal myocardial infarction 51 DAS# [002] 51 bronchopulmonary dysplasia 51 PCWP 51 glycosylated hemoglobin levels 51 subcutaneous insulin 51 n = 51 prospectively defined 51 Perforomist Inhalation Solution 51 mg dl 51 cTnT 51 glomerular filtration 51 iloprost 51 hypotensive 51 administered subcutaneously 51 ribavirin therapy 51 diastolic BP 51 repeat revascularization 51 diastolic pressure 51 lumbar spine bone 51 macrovascular events 51 intraocular pressure IOP 51 Pain Intensity 51 receiving ISENTRESS 51 hemoglobin A1c 51 placebo fluoxetine 51 octreotide LAR 51 CNS LS 51 lispro alone 51 VAPRISOL 51 nocturnal hypoglycemia 51 clomipramine 51 CHD mortality 51 #mm Hg 51 receiving golimumab 51 dyssynchrony 51 kg -1 51 oxygen desaturation 51 glucose tolerance 51 clodronate 51 isolated systolic hypertension 51 serum calcium levels 51 Scale EDSS score 51 AVODART 51 FDA defined valvulopathy 51 hip BMD 51 multivariate adjustment 51 umol L 51 COPD exacerbations 51 urinary N telopeptide 51 CANCIDAS 51 albumin excretion rate 51 #.#g/day 51 HAM D# scores 51 elevated ALT 51 SGOT 51 MetS 51 pharmacodynamic 51 MMSE scores 51 -#.# mmHg 51 dose titration 51 inotropic 51 cilostazol 51 oxygen saturation 51 sd = 51 urinary oxalate 51 statistically significant p = 51 viral kinetics 51 neurologic progression 51 carotid IMT 51 salmeterol fluticasone propionate 51 mg qd 51 platelet inhibition 51 ritonavir boosted 51 piperacillin tazobactam 51 sodium excretion 51 impaired renal 51 #OHD levels 51 Ejection Fraction 51 pulmonary artery pressure 51 REYATAZ r 51 concentration Cmax 51 rizatriptan 51 oral corticosteroids 51 thrombotic complications 51 undetectable viral load 51 p = .# [001] 51 mg ustekinumab 51 obstructive apnea 51 acutely decompensated congestive heart 51 antihypertensive therapy 51 atorvastatin #mg 51 myocardial infarction 51 platelet counts 51 ertapenem 51 urate lowering therapy 51 metabolic parameters 51 systolic function 51 albumin creatinine ratio 51 hyperglycemia 51 tinzaparin 51 bronchospasm 51 ribavirin RBV 51 diastolic blood pressure 51 serum IgG 51 Endothelial function 51 CCyR 51 sUA levels 51 NovoLog ® Mix 51 intravaginal ejaculatory latency 51 salmeterol HFA MDI 51 dexamethasone 51 Free Survival PFS 51 urinary albumin excretion 51 expiratory 51 μg L 51 serum CRP 51 pramipexole 51 fluorouracil 51 candesartan 51 inhaled budesonide 51 glycemia 51 pyridostigmine 51 antibody titer 51 sinus rhythm 51 HbA 1C 51 FENO 51 walk distance 6MWD 51 nonsignificant difference 51 rt PA 51 mucosal healing 51 BROVANA 51 budesonide formoterol 51 tertiles 51 OAB symptoms 51 Hb 51 bezafibrate 51 free survival PFS 51 neurocognitive function 51 Acetate Rectal Suppositories 51 normotensive 51 serum clusterin levels 51 inotropic agents 51 hypopneas 51 titrated glipizide 51 dizziness nausea diarrhea 51 bolus injection 51 urinary sodium excretion 51 serum leptin 51 #ng/ml 51 elevated creatinine 51 virologic responses 51 #mg BID [001] 51 gout flare 51 severe hypoglycemia 51 upper gastrointestinal bleeding 51 beclomethasone dipropionate 51 mU liter 51 echocardiographic 51 carvedilol 51 mIU mL 51 BPRS PSS 51 refractory ischemia 51 rFSH 51 recurrent genital herpes 51 budesonide 51 morphometric vertebral fractures 51 apnea hypopnea 51 oxygen saturations 51 intraocular pressure 51 preserved ejection fraction 51 perioperatively 51 endometrial thickness 50 cholesterol LDL C 50 mg/m2 50 serum potassium levels 50 CVD mortality 50 Baseline characteristics 50 glargine 50 ng ml 50 pioglitazone 50 μg liter 50 systemic hypotension 50 sputum eosinophils 50 CI #.#-#.# [001] 50 creatinine 50 tamsulosin 50 asthma exacerbations 50 urate levels 50 anticholinergics 50 BENICAR 50 Brief Psychiatric 50 intramuscularly 50 Left Ventricular Ejection Fraction 50 KRAS mutations occur 50 pegylated interferon 50 angiotensin converting enzyme inhibitors 50 Tiotropium 50 LDL C 50 recurrent atrial fibrillation 50 RLS symptoms 50 candesartan cilexetil 50 evaluable 50 mcg albinterferon alfa 2b 50 systolic diastolic blood 50 test OGTT 50 secondary efficacy endpoint 50 Median survival 50 q#h 50 recurrent venous thromboembolism 50 nighttime awakenings 50 Hemoglobin A1c HbA1c 50 experienced virologic failure 50 plasma concentration Cmax 50 angiotensin converting enzyme ACE 50 detemir 50 non inferiority 50 systolic blood pressures 50 dysfunction LVSD 50 linezolid 50 #OHD 50 Pharmacokinetic parameters 50 Expanded Disability Status 50 myocardial viability 50 #mg dose [001] 50 ZOMIG Nasal Spray 50 NNT = 50 univariate analysis 50 moderate hepatic impairment 50 beta blocker therapy 50 pravastatin 50 target vessel revascularization 50 certolizumab pegol 50 alpha blocker 50 ADCS CGIC 50 erectile function 50 advanced adenomas 50 hs CRP 50 highly emetogenic 50 perioperative mortality 50 min -1 50 PRADAXA #mg 50 nmol l 50 #Gy 50 fluticasone furoate 50 aldosterone antagonist 50 % CI #.#-#.# [001] 50 hyperoxia 50 peginterferon 50 μg d 50 fasting glucose 50 bronchoconstriction 50 UPDRS scores 50 GI motility 50 nonfasting triglyceride levels 50 primary aldosteronism 50 Severity Index PASI 50 mg/m2 dose 50 microg 50 intravenous bolus 50 bacteriuria 50 mg kg hr 50 clinically meaningful 50 intact parathyroid hormone 50 hemoglobin Hb 50 ug mL 50 lamivudine monotherapy 50 ARIXTRA 50 urine albumin 50 mean baseline A1C 50 COPD exacerbation 50 pooled comparator 50 coadministration 50 IU ml 50 secondary efficacy endpoints 50 crossclamp 50 maximal aerobic capacity 50 VO2max 50 seroprotection 50 CSBMs 50 daunorubicin 50 #mg QD [001] 50 unfractionated heparin UFH 50 p = #.# [003] 50 ADHF 50 MAS XR 50 MBq 50 amlodipine 50 ibandronate 50 myocardial infarction stroke 50 tenecteplase 50 elevated serum creatinine 50 3mg 50 zonisamide SR 50 inhalations twice 50 ventricular function 50 primary endpoint 50 mm Hg diastolic 50 plasma renin activity 50 acute myocardial infarction AMI 50 transaminase 50 arterial thromboembolic events 50 postprandial blood glucose 50 oral rivaroxaban 50 generalized edema 50 Elitek 50 μg dose 50 adenoma recurrence 50 inhaled fluticasone 50 Tumor shrinkage 50 HBeAg positive patients 50 Hb levels 50 lipid profiles 50 #.#ml [002] 50 infliximab 50 serum vitamin D 50 serum glucose 50 transaminases 50 hypoglycemic events 50 â ‰ ¥ 50 flutamide 50 oral allopurinol 50 subcutaneous enoxaparin 50 prothrombin 50 lamivudine refractory patients 50 cardiogenic shock 50 Pegasys ® 50 Subgroup analyzes 50 methotrexate monotherapy 50 oxcarbazepine 50 hemoglobin A1C 50 NT proBNP concentrations 50 mg eq 50 antibiotic prophylaxis 50 doxorubicin docetaxel 50 milrinone 50 quetiapine XR 50 pegylated interferon alfa 2b 50 fondaparinux 50 radiographic progression 50 isoprostane 50 tPSA 50 placebo dexamethasone 50 rapid virological response 50 active comparator 50 severe neutropenia 50 urinary calcium 50 esomeprazole 50 d dimer 50 myocardial infarction MI 50 blood glucose concentrations 50 pCR 50 oral prednisone 50 degarelix 50 discontinuations due 50 glucose lowering 50 oral antidiabetic drugs 50 TAXUS Express Stent 50 oral levofloxacin 50 antipsychotic efficacy 50 Platelet counts 50 NYHA Class III 50 cytogenetic response 50 ALND 50 6MWT 50 DMARD 50 cortisol concentrations 50 thyroxine 50 hydroxyvitamin D levels 50 #ug [001] 50 GH secretion 50 serum sodium concentration 50 antibody titers 50 elevated LDL cholesterol 50 inhaled corticosteroids 50 hyperkalemia 50 LEXIVA